Company intelligence / Profile preview

Lipocine Inc

Salt Lake City, Utah, United Statesir.lipocine.com ↗

Ownership: Public · LPCN
Development stage: Commercial

Overview

Lipocine has one FDA-approved product (TLANDO) for testosterone replacement therapy. Their lead candidate LPCN 1144 has completed Phase 2 clinical studies for NASH treatment. Other pipeline products are in various stages of development.

Therapeutic areas: GastroenterologyPsychiatryMen's HealthEndocrinologyWomen's HealthNeurology
Modalities: Oral prodrugssmall molecules
Industry: Biotech

Drug pipeline

7 assets

LPCN 1148

6 more assets in the full pipeline.

Request access →

Partnerships

Verity Pharmaceuticals (commercialization of TLANDO in the US)Antares Pharma Inc (previous licensing agreement for TLANDO)Gordon Silver Limited

Financials

Market cap: $19.5M
Total revenue: $190.1K
Enterprise value: $-3.8M

Beyond the preview

Go deeper on Lipocine Inc.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lipocine Inc.

Explore the full profile